Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Physilax
- Development stage
- Unknown
- Lead developer
- Aboca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Physilax is an oral combination formulation developed by Beste Wahl India, containing lactulose (10 g), wheat dextrin (3.5 g), fructo-oligosaccharides (2.5 g), and polydextrose (2.1 g). It is designed to relieve constipation, support bowel regularity, and promote overall digestive health. Lactulose acts as an osmotic laxative, drawing water into the colon to soften stools and facilitate bowel movements. The prebiotic fibers—wheat dextrin, fructo-oligosaccharides (FOS), and polydextrose—synergistically support the growth of beneficial gut microbiota, improve intestinal function, and maintain digestive balance.
- Brand names
- Physilax
Beyond the preview
Go deeper on Physilax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Physilax.